



MD
Prescriptives™

Omega MD

Molecularly Distilled Enteric Coated Omega 3

Highly concentrated and purified Omega 3 capsules. Enteric coated virtually eliminating fish smell and aftertaste. A potent anti-inflammatory, it supports cardiovascular health with improved platelet function, joint function, skin hydration, vascular blood flow to the brain, neuronal cell membranes and mood.*

OmegaMD contains EPA and DHA (omega-3 fatty acids from fish oil,) which promote cardiovascular health by supporting healthy triglyceride and lipid metabolism, maintaining healthy blood flow, and supporting healthy platelet function.* They support optimal joint function and skin hydration by maintaining healthy prostaglandin and leukotriene production.*

EPA and DHA are important components of neuronal cell membranes and vascular flow to the brain.* Studies suggest that optimal concentrations of omega-3 fatty acids in red blood cell membranes are associated with emotional well-being.* Both epidemiological and double-blind placebo-controlled trials indicate that omega-3 fatty acids support a positive mood.* Harvard studies support the use of these at 2.5 grams per day for general maintenance and at higher doses to support cardiac, insulin efficiency, neurological, joint and skin conditions.*

Specific special features:

- **Enteric-coated gelcaps:** Research has shown (Dig Dis Sci. 1994;39:2589-94.) that enteric-coated gel caps have up to three times the bioavailability of regular omega gelcaps. Those who experience nausea or reflux from other fish oils should find this enteric coated, odor controlled soft gel easier to tolerate.*

Suggested Use: Take one softgel 1-4 times daily or as directed by your healthcare practitioner.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

References

1. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. *Dig Dis Sci* 1994;39:2589-94.
2. Mickleborough, et al. Protective Effect of Fish Oil Supplementation on Exercise-Induced Bronchoconstriction in Asthma. *Chest* 2006;129:39-49.
3. Nemets H, et al. Omega-3 Treatment of Childhood Depression: A Controlled, Double-Blind Pilot Study. *Am J Psychiatry*. 2006;163:1098-1100.
4. Ryan AS, Nelson EB. Assessing the Effect of Docosahexaenoic Acid on Cognitive Function in Healthy, Preschool Children: A Randomized, Placebo-Controlled, Double-Blind Study. *Clin Ped*. 2008;474): 355-62.
5. Helland et al. Maternal Supplementation with Very-Long-Chain n-3 Fatty Acids During Pregnancy and Lactation Augments Children's IQ at 4 Years of Age. *Pediatrics*. 2003;111:e39.
6. James I. Ausman, MD, PhD (Editor). Why omega-3 fatty acids are important to neurosurgeons. *Surg Neuro*. 2006;65:325.
7. Stamp L, James M, Cleland L. Diet and Rheumatoid Arthritis: A Review of the Literature. *Semin Arthritis Rheum*. 2005;35:77-94.
8. Maroon J, et al. Omega-3 Fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. *PA Surgical Neurology* 2006;65:311-26.
9. Holub BJ. Treating Triglyceridemia. *Can Medica Assoc J*. 2007;177:604.
10. Garrioch CF, Garrioch GF, Holub JA, Holub BJ. EPA/DHA Supplementation Improves Postprandial Triglyceride Responses

In Hypercholesterolemic Patients On Statin Therapy.

Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada; 2 Plaza 69 Medical Clinic, Sudbury, Ontario, Canada ISSFAL 2008, Kansas, MI Treatment: Patients received placebo capsule or 3000 mg/day (EPA+DHA) for 21 days.

11. Berbert AA, Kondo CR, Almendra CL, et al. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. *Nutrition*. 2005;21(2):131-136.
12. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. *JAMA*. 2006 Jun 14;295(22):2613-9.
13. Burns CP, Halabi S, Clamon G, et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. *Cancer*. 2004 Jul 15;101(2):370-8.
14. Cederholm T, Palmblad J. Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? *Curr Opin Clin Nutr Metab Care*. 2010;13(2):150-5.
15. Di Minno MN, et al. Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. *Thromb Haemost*. 2010;104(4):664-80.
16. Duffy EM, Meenagh GK, McMillan SA, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. *J Rheumatol*. 2004;31(8):1551-6.
17. Erkkila AT, Lichtenstein AH, Mozaffarian D, et al. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. *Am J Clin Nutr*. 2004;80(3):626-32.
18. Heird WC. Do you need a supplement of docosahexaenoic acid or an n-3 long-chain polyunsaturated fatty acid? *Am J Clin Nutr*. 2010;91(4):827-8.
19. Joensen AM, et al. Dietary intake of total marine n-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary syndrome - a cohort study. *Br J Nutr*. 2010;103(4):602-7.
20. Koletzko B, et al. Dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in children - a workshop report. *Br J Nutr*. 2010;103(6):923-8.
21. Lim WS, Gammack JK, Van Niekerk J, et al. Omega 3 fatty acid for the prevention of dementia. *Cochrane Database Syst Rev*. 2006 Jan 25;(1):CD005379.
22. Mostad IL, Bjerve KS, Bjorgaas MR, et al. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. *Am J Clin Nutr*. 2006 Sep;84(3):540-50.
23. Musa-Veloso K, et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. *Nutr Rev*. 2010;68(3):155-67.
24. Olza J, et al. Influence of an eicosapentaenoic and docosahexaenoic acid-enriched enteral nutrition formula on plasma fatty acid composition and biomarkers of insulin resistance in the elderly. *Clin Nutr*. 2010;29(1):31-7.
25. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. *Eur Neuropsychopharmacol*. 2003;13(4):267-71.
26. Simopoulos A. Omega-3 fatty acids in health and disease and in growth and development. *Am J Clin Nutr*. 1991;54:438-63.
27. Pepping J. Omega-3 essential fatty acids. *American Journal of Health-System Pharmacy* 1999 Apr 15;56:719-24.
28. Uauy-Dagach R, Valenzuela A. Marine oils: the health benefits of n-3 fatty acids. *Nutr Rev*. 1996 Nov;(54):S102-S108.
29. Connor WE. Importance of n-3 fatty acids in health and disease. *American J Clin Nutr*. 2000 Jan;71(suppl):171S-75S.
30. DiGiacomo RA, et al. Fish-oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-Blind, Controlled, Prospective Study. *Am J Med*. 1989 Feb;86:158-64.
31. Levine BS. Most frequently asked questions about DHA. *Nutrition Today*. Vol. 32, November/December 1997, pp. 248-49
32. Kalmijn S, et al. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. *Am J Epidem*. 1997 Jan 1;145:33-41.
33. Kalmijn S, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. *Ann Neuro*. 1997 Nov;42(5):76-82.
34. Yehuda S, et al. Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. *Int'l J Neurosci*. 1996 Nov;87(3-4):141-9.
35. Edwards R, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affec Disorders*. 1998 Mar;48:149-55.
36. Hibbeln JR. Fish consumption and major depression. *The Lancet*. 1998 Apr 18;351:1213 (correspondence).
37. Calabrese JR, et al. Fish oils and bipolar disorder. *Arch Gen Psychiatry*. 1999 May;56:413-14 (commentary).
38. Jensen CL, et al. Effect of docosahexaenoic acid

- supplementation of lactating women on the fatty acid composition of breast milk lipids and maternal and infant plasma phospholipids. *Am J Clin Nutr.* 2000 Jan;71 (suppl):292S-99S.
39. Cunnane SC, et al. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. *Lipids.* 2000 Jan;35:105-11.
40. Hodge L, et al. Consumption of oily fish and childhood asthma risk. *Med J Australia.* 1996 Feb 5;164:137-40.
41. Broughto, KS, et al. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. *Am J Clin Nutr.* 1997 Apr;65:1011-17.
42. Daviglus ML, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. *NEJM.* 1997 Apr 10;336:1046-53.
43. Christensen JH, et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction. *Brit Med J.* 1996 Mar 16;312:677-78.
44. Salachas A, et al. Effects of low-dose fish oil concentrate on angina, exercise tolerance time, serum triglycerides, and platelet function. *Angiology.* 1994 Dec;45:1023-31.
45. McManus RM, et al. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes. *Diabetes Care.* 1996 May;19:463-67.
46. Appel LJ, et al. Does supplementation of diet with "fish oil" reduce blood pressure? *Arch Int Med.* 1993 Jun 28;153:429-38.
47. Cobiac L, et al. Effects of dietary sodium restriction and fish oil supplements on blood pressure in the elderly. *Clin Exp Pharmacol Physiol.* 1991 May;18: 265-68.
48. Kremer JM, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis: A double-blinded, controlled, crossover study. *Ann Int Med.* 1987 Apr;106: 497-503.
49. Geusens P, et al. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis: a 12-month, double-blind, controlled study. *Arthritis and Rheumatology.* 1994 Jun;37:824-29.
50. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study. *Am J Gastroent.* 1992 Apr;87:432-37.
51. Simonsen N, et al. Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC Study. *Am J Epidem.* 1998;147(4):342-52 .
52. Cave WT. Dietary omega-3 polyunsaturated fats and breast cancer. *Nutrition.* 1996 Jan;12 (suppl):S39-42.
53. Fernandez-Banares F, et al. Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. *Gut.* 1996;38:254-59.
54. Wigmore SJ, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. *Nutrition.* 1996 Jan;12 (suppl):S27-30.